NasdaqCM - Delayed Quote USD

Palvella Therapeutics, Inc. (PVLA)

Compare
13.50
+0.19
+(1.43%)
At close: January 30 at 4:00:00 PM EST
13.01
-0.54
(-3.99%)
Pre-Market: 5:13:39 AM EST
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
Operating Expense
9,088.00
11,869.00
18,040.00
Operating Income
-9,088.00
-11,869.00
-18,040.00
Net Non Operating Interest Income Expense
8,039.00
6,265.00
-10,364.00
Other Income Expense
23,916.00
24,295.00
-174.00
Pretax Income
22,867.00
18,691.00
-28,578.00
Tax Provision
--
--
-1,026.00
Net Income Common Stockholders
22,091.00
17,915.00
-27,552.00
Diluted NI Available to Com Stockholders
22,091.00
17,915.00
-27,552.00
Basic EPS
1.97
1.60
-2.46
Diluted EPS
1.97
1.60
-2.46
Basic Average Shares
11,221.31
11,221.31
11,221.31
Diluted Average Shares
11,221.31
11,221.31
11,221.31
Total Operating Income as Reported
-9,088.00
-11,869.00
-18,040.00
Total Expenses
9,088.00
11,869.00
18,040.00
Net Income from Continuing & Discontinued Operation
22,867.00
18,691.00
-27,552.00
Normalized Income
22,355.00
18,206.00
-27,262.77
Net Interest Income
8,039.00
6,265.00
-10,364.00
EBIT
-9,467.00
-11,869.00
-18,040.00
EBITDA
-9,467.00
-11,869.00
-18,040.00
Net Income from Continuing Operation Net Minority Interest
22,867.00
18,691.00
-27,552.00
Total Unusual Items Excluding Goodwill
512.00
485.00
-300.00
Total Unusual Items
512.00
485.00
-300.00
Normalized EBITDA
-9,979.00
-12,354.00
-17,740.00
Tax Rate for Calcs
--
--
0.00
Tax Effect of Unusual Items
--
--
-10.77
12/31/2022 - 1/2/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers